TABLE 2

Drugs that have elicited an AD-like effect in the FSL rat after chronic treatment

Drug (mg/kg)	Dose	Drug Class	Change in Swimming	References
Desipramine	5	Tricyclic	Significant increase	Pucilowski and Overstreet, 1993
Desipramine	5	Tricyclic	Significant increase	Schiller et al., 1992
Desipramine	5	Tricyclic	Significant increase	Zangen et al., 2001
Sertraline	5.7	SSRI	Significant increase	Pucilowski and Overstreet, 1993
Imipramine	15	Tricyclic	Significant increase	Schiller et al., 1992
DFP	1	Anticholinesterase	No Change	Schiller et al., 1992
SSR125543	3, 30	CRF1 antagonist	Significant increase	Overstreet and Griebel, 2004^{^a}
SSR58611A	1, 3	β2 NA agonist	Significant increase	Overstreet et al., 2008^{^a}
Nemifitide	0.3	Analog of MIF	Significant increase	Overstreet et al., 2004a^{^a}
Amphetamine	2	Stimulant	No change	Overstreet et al., 1995
Scopolamine	2	Anticholinergic agent	No change	Overstreet et al., 1995
SSR149415	10, 30	V1b antagonist	Significant increase	Overstreet and Griebel, 2005
CP154,526	10 × 2	CRF1 antagonist	Significant increase	Overstreet et al., 2004b^{^a}
Citalopram	5, 10	SSRI	Significant increase	Overstreet et al., 2004b^{^a}
Saredutant	1, 10	NK2 antagonist	Significant increase	Overstreet et al., 2010a^{^a}
Paroxetine	7.5	SSRI significant	Increase	Mork et al., 2011
Paroxetine	7.5	SSRI	Significant increase	Zangen et al., 2001
Ondansetron	1, 10	5-HT₃ antagonist	Significant increase	Mork et al., 2011
Lu AA33810	3, 10	NPY Y5 antagonist	Significant increase	Walker et al., 2009
S 20304	1, 20	Melatonin agonist	Significant increase	Overstreet et al., 1998a
S 20928	1, 10	Melatonin antagonist	No change	Overstreet et al., 1998a
Inositol	1200	Precursor to inositol	Significant increase	Einat et al., 2002
Nicotine	0.4	Nicotine agonist	Significant increase	Tizabi et al., 1999
NGF	Many	Trophic factor	Significant increase	Overstreet et al., 2010b

CRF1, corticotropin-releasing factor 1; MIF, melanocyte inhibiting factor; NGF, nerve growth factor; NK2, neurokinin 2; SSRI, selective serotonin reuptake inhibitor; V1b, vasopressin V1b receptor; SSR125543, 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine; SSR58611A, amibegron (ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate); SSR149415, nelivaptan ((2S,4R)-1-[(3R)-5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl-3-(2-methoxyphenyl)-2-oxo-indolin-3-yl]-4-hydroxy-N,N-dimethyl-pyrrolidine-2-carboxamide); CP154526, N-butyl-N-ethyl-2,5-dimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[3,2-e]pyrimidin-4-amine; Lu AA33810, N-[(trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl)methyl]methanesulfonamide; S 20304, N-(2)7-methoxy-1-naphthyl)ethyl)cyclopropanecarboximide; S 20928, N-(2-(1-naphthyl)ethyl)cyclobutanecarboximide.
↵^a These studies included a tricyclic and/or an SSRI as a positive control, and the study drugs significantly increased swim test behavior (reduced immobility).